Illumina has recently advanced its plan to divest its cancer-diagnostics unit, a move intended to ease regulatory pressure and sharpen its focus on core DNA sequencing and microarray technologies.

Illumina is welcoming a new addition to its DNA sequencing lineup, with a pair of accessible benchtop instruments that incorporate the tech and chemistry used by its largest, top-of-the-line machines.

Nearly a year after leaving his position as longtime director of the National Human Genome Research Institute (NHGRI), Eric ...

A streamlined, automated process helps scientists coordinate site-ready production-level whole genome sequencing results.

Illumina, whose EMEA head office is at Granta Park in Cambridge, has released Illumina Connected Multiomics, a powerful cloud ...

Illumina Taiwan Biotechnology Co., Ltd., and Precision Medicine Asia, Limited (PREMIA), a leading Asian cancer clinical-genomic screening network, today announced the formation of a strategic ...

If you are wondering whether Illumina's current share price offers fair value or room for mispricing, you are not alone. This article walks through what the numbers actually say about the stock.

Aug 13 (Reuters) - Illumina (ILMN.O), opens new tab said on Tuesday it has partnered with the Broad Institute to develop new kits that will allow large-scale gene ...

San Diego gene sequencing giant Illumina is investing more in artificial intelligence to fuel the company’s growth strategy through a partnership with Nvidia. Nvidia — the Santa Clara tech company at ...